Quantcast

Latest Genmab Stories

2009-04-30 05:00:00

PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009. Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share.

2009-04-07 11:42:00

MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015 SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis, lupus, gout and psoriatic arthritis. To develop this analysis, entitled "Thought Leader...

2009-03-10 08:00:00

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets.

2009-02-25 15:00:00

PRINCETON, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter and year ended December 31, 2008.

2009-01-30 10:00:00

Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S.

2009-01-23 09:08:00

SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing critical strategic insight for companies developing therapies to treat hematologic malignancies.

2008-12-08 12:59:00

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec.

2008-12-01 07:27:00

COPENHAGEN, December 1 /PRNewswire/ -- A strong pipeline makes the Copenhagen Region biotech cluster well prepared for the challenges ahead. With 185 drug candidates in preclinical and clinical development, Denmark ranks third in Europe.

2008-11-04 06:00:10

Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma.

2008-10-30 18:00:29

Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008.


Word of the Day
pudic
  • Easily ashamed, having a strong sense of shame; modest; chaste.
  • Of or pertaining to the external organs of generation.
The word 'pudic' comes from French pudique, from Latin pudīcus, from pudet ("it shames"). (Wiktionary)
Related